Kenvue Inc. is dealing with another challenge to a top-selling product as it attempts to close its $40 billion acquisition by ...

Shares of Kenvue Inc. KVUE slid 1.04% to $17.10 Thursday, on what proved to be an all-around positive trading session for the ...

Kimberly-Clark (KMB) stock faces risks from the $48.7B Kenvue acquisition, high debt, and weak growth. Learn why analysts ...

Texas has long been home to companies that grow not because the government clears the road for them, but because they innovate, compete, and persevere. Kimberly-Clark, based in Irving, is one of those ...

Kimberly-Clark's latest valuation update reflects only a slight trim to its fair value estimate, nudging it from about ...

KVUE's stock performance has suffered from legacy investor selling, management turnover, litigation risks, and a profit ...

"I will not allow Big Pharma to operate above the law or put their greed ahead of Texans’ well-being," said Paxton.

Kenvue has a lower P/E than the aggregate P/E of 55.57 of the Personal Products industry. Ideally, one might believe that the ...

A Texas judge has ordered Tylenol-maker Kenvue Inc. and its former parent Johnson & Johnson to register with the Texas Secretary of State or risk being barred from doing business in the state.

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.Kenvue shareholders will receive $3.50 per share in ...